When was Resverlogix founded?

Resverlogix was founded in 2001 and raised its 1st funding round 9 years after it was founded.

Where is Resverlogix located?

Resverlogix is headquartered in Calgary, Canada.

How many employees does Resverlogix have?

As of Mar 31, 2026, the latest employee count at Resverlogix is 21.

Is Resverlogix a funded company?

Resverlogix is a funded company, having raised a total of $129M across 19 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Jan 2010.

When was the latest funding round of Resverlogix?

Resverlogix's latest funding was a $***** Post IPO round on Oct 06, 2020, with participation from 0 investor.

Where does Resverlogix rank among its competitors?

Resverlogix ranks 207th amongst 926 active competitors, of which 286 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Tenaya Therapeutics, which secured $8M in Feb, 2025.

Who are the top competitors of Resverlogix?

Resverlogix's top competitors include Alnylam, BridgeBio and Alexion. Among them, Tenaya Therapeutics secured the most recent funding round in February, 2025.

Resverlogix - 2026 Company Profile, Team, Funding & Competitors

Resverlogix is a public company based in Calgary (Canada), founded in 2001 by Norman Wong and Don McCaffrey. It operates as a Provider of small molecule BET-inhibitors for CV disease for treating diabetes. Resverlogix has raised $129M in funding. The company has 926 active competitors, including 286 funded and 262 that have exited. Its top competitors include companies like Alnylam, BridgeBio and Alexion.

Company Details

Resverlogix is a provider of small molecule BET-inhibitors for CV disease for treating diabetes. It is a late clinical-stage biopharma developing selective BET-inhibitors for CV disease in Diabetes patients. The company's lead candidate is Apabetalone (RVX-208), a first-in-class, small-molecule selective BET bromodomain inhibitor (selective to BRD4-BD2). The company has a proprietary epigenetics drug development platform and has identified additional compounds based on targeting BET (Bromodomain and extra-terminal Domain) proteins.

Website: www.resverlogix.com/
Social
Email ID: *****@resverlogix.com

Key Metrics

Founded Year

2001

Location

Calgary, Canada

Stage

Public

Total Funding

$129M in 19 rounds

Latest Funding Round

Post IPO, Oct 06, 2020, $*****

Investors

NGN Capital & 4 more

Ranked

207^th among 926 active competitors

Employee Count

21 as on Mar 31, 2026

Similar Companies

Alnylam & 1027 more

Exit Details

Public

View Resverlogix's full profile

Resverlogix got listed on Jan 17, 2005.

Click here to take a look at Resverlogix's IPO in detail

Resverlogix has raised a total funding of $129M over 19 rounds. Its first funding round was on Jan 2010. Resverlogix has 5 institutional investors.

Here is the list of recent funding rounds of Resverlogix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 06, 2020	4245364	Post IPO	3212040	8174308	6138658	5524257
Aug 14, 2020	6616971	Post IPO	4481642	2072278	7791522	Shenzhen Hepalink Pharmaceutical
Sep 27, 2019	6466855	Conventional Debt	3516589	1661011	5551273	4051202

Access funding benchmarks and valuations. Sign up today!

View details of Resverlogix's funding rounds and investors

The founders of Resverlogix are Norman Wong and Don McCaffrey.

Here are the details of Resverlogix's key team members:

Norman Wong: Co-Founder & Chief Scientific Officer of Resverlogix. They are also an angel investor in 1 startup.
Don McCaffrey: President, Co-Founder & CEO of Resverlogix.

View details of Resverlogix's Founder profiles and Board Members

Resverlogix's employee count trend

Resverlogix has 21 employees as of Mar 26. Here is Resverlogix's employee count trend over the years:

Uncover Resverlogix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Resverlogix include Alnylam, BridgeBio and Alexion. Here is the list of Top 10 competitors of Resverlogix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
2nd	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	79/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Invesco, Allen & Company & 9 others	79/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	76/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Omega Funds & 17 others	75/100
6th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Forbion & 20 others	72/100
7th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	70/100
8th	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, RA Capital Management & 7 others	70/100
9th	Orchard Therapeutics 2015, London (United Kingdom), Acquired	Developer of gene therapies for treating rare diseases	$440M	Baillie Gifford, ORI Capital & 30 others	70/100
10th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 9 others	70/100
207th	Resverlogix 2001, Calgary (Canada), Public	Provider of small molecule BET-inhibitors for CV disease for treating diabetes	$129M	NGN Capital, Shenzhen Hepalink Pharmaceutical ... & 3 others	47/100